Equity Research Database

Institutional Investment Pitches

Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.

Atrium Research's investment thesis on Cannara Biotech Inc. ($LOVE.TO) — Q2 2026 | Buyside Digest

$LOVE.TONASDAQCannara Biotech Inc.

NEUTRAL

Atrium Research—LOVE.TO

Fund Letter

Q2 2026

Published July 17, 2026

$1.88USD

-5.5% vs last month

$1.90Pitched

-1.1% since pitch

Market Cap$191.6M

P/E (TTM)N/A

52-Wk RangeN/A

Div. YieldN/A

Cannara Biotech rebounded strongly in Q3 with record gross cannabis revenue, robust margins, and expanded national distribution. The company also...

— Ben Pirie & Nicholas Cortellucci

BSD Research Exclusive

Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($55/mo) and Pro subscribers.

6,000+ Institutional Pitches

Proprietary AI Analysis

100 Letter Unlocks/Cycle

Already a Research or Pro subscriber? Sign In

◆ Keep Reading

Other investors who've written on Cannara Biotech Inc.

No other institutional pitches found for this ticker yet.